Actelion Pharmaceuticals has filed a request with the European Medicines Agency for the expanded approval of Opsumit (macitentan) as a treatment for adults with moderate to severe inoperable chronic thromboembolic pulmonary hypertension (CTEPH), the company announced. If the EMA approves the submitted type II variation to…
News
Levosimendan, an investigational therapy for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), was found to improve workings of the kidneys in PH-HFpEF patients with kidney impairment in a Phase 3 clinical trial. Findings from the study, “Differential effects of levosimendan and dobutamine on glomerular…
Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile over both immediate-release ralinepeg capsules and approved immediate-release medication Uptravi (selexipag), according to two Phase 1 trials in healthy volunteers. Pharmacokinetics (PK) refer to how a drug is absorbed,…
Antidote Technologies, a digital health company, and phaware global association, an organization advocating for pulmonary hypertension (PH) awareness, will join forces to create a new recruitment system for pharmaceutical companies and contract research organizations (CROs) to enroll patients with chronic lung diseases in their clinical trials. The…
More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment administration, an observational study reports. The study looked at the inhalation behavior of PAH patients who were switched from…
Evaluation of Midkine (MDK) and Follistatin-like 3 (FSTL3) protein levels in the blood can help identify patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), researchers suggest. The study, “Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis” was published in the journal…
Intravenous treatment with the approved heart failure medicine milrinone leads to significant improvements in heart structure and function in patients with mild-to-moderate pulmonary hypertension (PH) due to left heart disease, a study has found.” The report titled “Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients…
Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH). The U.S. Food and Drug Administration gave Mylan final approval for its abbreviated new drug application for tadalafil,…
For patients with pulmonary hypertension (PH) who have undergone nonheart surgeries, self-reporting of walking and stair climbing ability can predict the risk of postsurgical complications, a study found. Researchers say this simple and noninvasive assessment can help identify PH patients at high risk of complications,…
Treatment with Phps-1, which inhibits a protein called Shp2, was able to alleviate specific symptoms of pulmonary arterial hypertension (PAH) in a rat model, suggesting that Shp2 may be a potential therapeutic target for PAH treatment, a study reports. The study, “Inhibition of Shp2 ameliorates monocrotaline-induced…
The U.S. Food and Drug Administration has granted orphan drug designation to Livantra, a new formulation of an already approved treatment outside the U.S. for another indication, for the treatment of pulmonary arterial hypertension (PAH), according to the…
Inhibition of proteins that regulate gene expression — called BET — were found to ease pulmonary hypertension (PH) in a rat model of chronic obstructive pulmonary disease (COPD), a study reports. The study, “Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined…
